Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 16, 2024, titled "Zydus receives Final Approval from the USFDA for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg".
Press Release Feb 16 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Isosorbide Mononitrate Extended-Release Tablets in various dosages. This medication is intended to prevent chest pain in patients with coronary artery disease and will be manufactured at their facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 09 2024
- Press Release Feb 08 2024
- Press Release Jan 30 2024
- Press Release Jan 25 2024
- Press Release Jan 19 2024
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Feb 26 2024
- Press Release Mar 13 2024
- Press Release Mar 14 2024
- Press Release Mar 16 2024
- Press Release Mar 23 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences